Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of PF-06939926 in Duchenne Muscular Dystrophy
2019-002921-31Phase 3Unknown
- Sponsor
- Pfizer
- Start
- Jul 2020
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing PF-06939926 with Placebo (2 arms). Primary endpoint: Change from Baseline at Week 52 in the NSAA total score. Status: unknown.
02
Drugs
fordadistrogene movaparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2019-002921-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002921-31.